Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Promis Neurosciences Inc

(TSX: PMN.TO)
Add to Portfolio
unch (unch)
as of Sep 18, 2019

Last 0.23
Change unch (unch)
Open 0.23
Prev. Close 0.23
Today's Range
0.23
0.23
52wk Range
0.18
0.44
Volume 176,500
Avg Volume 172,891

Perfomance Comparison

Name Today 3-Month 1-Year
PMN.TO unch unch -20.69%
$TXCX -0.20% +2.05% +3.73%
$TXSC -0.11% +2.10% +4.75%
DJIA +0.13% +1.36% +3.43%
S&P 500 +0.03% +0.91% +3.53%

Key Statistics

Annual EPS -0.04
Dividend Yield N/A
P/E Ratio N/A
Market Capitalization, $K 60,124
Weighted Alpha -27.39
Standard Deviation unch
Profit Margin -21,617.02%
Beta -1.83

Growth Rates

YTD -14.81%
1-Year -28.12%
3-Year +64.29%

Opinion

Sell Hold Buy

Recent Headlines

ProMIS Neurosciences Executive Chairman Eugene

Globe Newswire via COMTEX - Mon Sep 16, 07:30AM EDT
TORONTO and CAMBRIDGE, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oli(full story)
ARFXF: 0.1745 (-0.0028), PMN.TO: 0.23 (unch)

ProMIS Neurosciences to Present at H.C. Wainwright

Globe Newswire via COMTEX - Tue Sep 03, 07:30AM EDT
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs(full story)
ARFXF: 0.1745 (-0.0028), PMN.TO: 0.23 (unch)

ProMIS Neurosciences to Present at HC Wainwright

PR Newswire via COMTEX - Tue Sep 03, 07:30AM EDT
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs(full story)
ARFXF: 0.1745 (-0.0028), PMN.TO: 0.23 (unch)

ProMIS Neurosciences Appoints Internationally

Globe Newswire via COMTEX - Tue Aug 27, 07:30AM EDT
TORONTO and CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic olig(full story)
ARFXF: 0.1745 (-0.0028), PMN.TO: 0.23 (unch)

ProMIS Neurosciences Announces Second Quarter 2019

Globe Newswire via COMTEX - Tue Aug 13, 07:30AM EDT
Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease(full story)
ARFXF: 0.1745 (-0.0028), PMN.TO: 0.23 (unch)